Abstract:The aim of this study was to examine basal ganglia volumes and regional cerebral blood flow in asymptomatic subjects at-risk for Huntington's disease who had undergone genetic testing. We determined which measures were the best 'markers' for the presence of the mutation and for the onset of symptoms. Twenty subjects who were Huntington's disease gene mutation-positive and 24 Huntington's disease gene mutation-negative participants, all of whom had a parent with genetically confirmed Huntington's disease, and w… Show more
“…The main new finding is that smaller basal ganglia volumes in gene carriers were associated with subtle motor abnormalities and worse performances on psychomotor tasks. The results confirm previous MRI studies showing that gene carriers in the preclinical stage of HD have a smaller caudate nucleus, putamen and globus pallidus compared to non-gene carriers [9,10,12,20,37]. However, we could not confirm the finding that thalamus volume was reduced in gene carriers [12].…”
Section: Discussioncontrasting
confidence: 69%
“…■ Key words Huntington's disease · preclinical · imaging · cognition made [8][9][10][11][12]. Approaching disease onset globus pallidus volume and thalamus volume was found to be reduced as well [8,9,12].…”
In line with previous research we demonstrated that basal ganglia abnormalities precede overt disease manifestation of HD. Besides we showed that smaller basal ganglia volumes are related to subtle motor abnormalities and worse psychomotor performance in gene carriers without clinical diagnosis. Motor and psychomotor measures may be suitable clinical markers in future neuroprotective trials when combined with volumetric imaging.
“…The main new finding is that smaller basal ganglia volumes in gene carriers were associated with subtle motor abnormalities and worse performances on psychomotor tasks. The results confirm previous MRI studies showing that gene carriers in the preclinical stage of HD have a smaller caudate nucleus, putamen and globus pallidus compared to non-gene carriers [9,10,12,20,37]. However, we could not confirm the finding that thalamus volume was reduced in gene carriers [12].…”
Section: Discussioncontrasting
confidence: 69%
“…■ Key words Huntington's disease · preclinical · imaging · cognition made [8][9][10][11][12]. Approaching disease onset globus pallidus volume and thalamus volume was found to be reduced as well [8,9,12].…”
In line with previous research we demonstrated that basal ganglia abnormalities precede overt disease manifestation of HD. Besides we showed that smaller basal ganglia volumes are related to subtle motor abnormalities and worse psychomotor performance in gene carriers without clinical diagnosis. Motor and psychomotor measures may be suitable clinical markers in future neuroprotective trials when combined with volumetric imaging.
“…There is evidence of distributed gray matter pathology and progressive white matter pathology before the clinical onset of HD (5,19), and loss of basal ganglia volume has also been reported in asymptomatic individuals with HD mutation (20)(21)(22)(23)(24), indicating that striatal neuronal loss occurs before or early during the clinical course.…”
Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder that affects the striatum most severely. However, except for juvenile forms, relative preservation of the cerebellum has been reported. The objective of the present study was to perform MRI measurements of caudate, putamen, cerebral, and cerebellar volumes and correlate these findings with the length of the CAG repeat and clinical parameters. We evaluated 50 consecutive patients with HD using MRI volumetric measurements and compared them to normal controls. Age at onset of the disease ranged from 4 to 73 years (mean: 43.1 years). The length of the CAG repeat ranged from 40 to 69 (mean: 47.2 CAG). HD patients presented marked atrophy of the caudate and putamen, as well as reduced cerebellar and cerebral volumes. There was a significant correlation between age at onset of HD and length of the CAG repeat, as well as clinical disability and age at onset. The degree of basal ganglia atrophy correlated with the length of the CAG repeat. There was no correlation between cerebellar or cerebral volume and length of the CAG repeat. However, there was a tendency to a positive correlation between duration of disease and cerebellar atrophy. While there was a negative correlation of length of the CAG repeat with age at disease onset and with striatal degeneration, its influence on extrastriatal atrophy, including the cerebellum, was not clear. Extrastriatal atrophy occurs later in HD and may be related to disease duration.
“…There is also evidence of atrophy in many other brain structures including the frontal lobes, thalamus, globus pallidus and insula [2,12,28,42] with abnormalities in both white matter [9,31] and cortical grey matter [39] during the pre-manifest stage. However, there is still discussion about the relationship between these abnormalities and the onset of disease or whether they could also have some developmental basis.…”
Section: Predicting Clinical Diagnosis In Hd Neuropathologymentioning
Unlike most neurodegenerative disorders, individuals at risk from Huntington's disease can be identified prior to the onset of clinical signs of the disease by virtue of it being an autosomal dominant condition. This provides the hypothetical opportunity to delay disease onset and/or slow down the progression of the disease in the very early stages ahead of overt features of disease. To help prepare for therapeutic trials of disease-modifying compounds, extensive work has gone into (1) finding ways of better predicting the onset of disease in pre-manifest HD gene carriers (PMGC), (2) defining the extent of non-motor features of HD and (3) identifying robust and reliable tests by which to measure disease progression. In this short review, we summarise some of the major findings in this area of clinical research.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.